ArticleFrontiers in medicine2026
Comparison of risks and costs of undiagnosed and diagnosed chronic kidney disease patients after the initiation of kidney replacement therapy in subsequent years. A Hungarian nationwide study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Despite high prevalence, chronic kidney disease (CKD) often remains undiagnosed and untreated, leading to an increased risk of end-stage kidney disease (ESKD), kidney replacement therapy (KRT), comorbidities, and premature death. In this retrospective nationwide study, we examined whether a lack of CKD diagnosis is associated with adverse post-KRT outcomes among newly dialyzed patients with chronic ESKD in Hungary. Methods: Two cohorts-undiagnosed (CKD naive) and diagnosed (CKD non-naive) patients (aged > 18 years)-were compared. Cohorts were defined based on pre-dialysis (>2 months) diagnosis-coding and erythropoietin therapy. We compared the risk of primary endpoints after KRT initiation (including all-cause mortality, acute myocardial infarction, stroke, hospitalization for heart failure (HHF), lower limb amputation (LLA), cancer, kidney transplantation) using propensity score subclassification for 56 confounders (matched data). We also examined exploratory endpoints (total healthcare costs, key comorbidities, laboratory testing, medications) over 5 years pre-KRT and/or post-KRT (unmatched data). Data were collected from the National Health Insurance Fund registry. Results: We identified 38,013 ESKD patients on KRT in 2009-2023, of whom 10,810 started dialysis in 2014-2018. Among these, 33% were undiagnosed (CKD naive). This group experienced more adverse events as early as 3 months post-KRT, including higher deaths (27% vs. 7.8%), HHF (18.8% vs. 11.1%), and cancers (11.2% vs. 2.1%). They also had fewer kidney transplantations (4.6% vs. 14%) at 72 months than the CKD non-naive group. Median survival was markedly shorter for CKD naive patients (3 months) than for CKD non-naive patients (34 months). Cox regression revealed higher risks for CKD naive patients for all-cause mortality [HR: 3.66 (CI: 3.12-4.29), Discussion: Undiagnosed CKD patients experience significantly worse outcomes post-KRT and incur higher long-term costs related to inpatient care. These findings underscore the need for early CKD diagnosis and timely interventions to improve survival and optimize healthcare resource utilization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.